Functional Brands Reduces Preferred Stock Conversion Price, Capitalizes Unpaid Cash as Unsecured Debt
MEHA is trading near its 52-week low of $0.083 (6.8% above the low) on elevated volume (44× avg).
Summary
Functional Brands Inc. reduced the conversion price for its Series C Preferred Stock and converted unpaid cash obligations into unsecured debt, indicating financial strain and increased dilution risk for common shareholders.
Key Events · Financing and Capital Events · MEHA
-
Preferred Stock Conversion Price Reduced
The conversion price for Series C Convertible Preferred Stock was lowered to $0.1636 per share, replacing previous tiered prices. This price was the market price on May 11, 2026, but is now above the current market price of $0.0883.
-
Below-Price Conversion Prohibition Waived
The company waived the prohibition on converting preferred stock below the market price, allowing holders to convert at $0.1636 even if the common stock trades lower, increasing the likelihood of dilution for common shareholders.
-
Unpaid Cash Capitalized as Unsecured Debt
Unpaid cash consideration from a prior exchange agreement will be added as additional, unsecured principal to existing notes. This indicates liquidity issues and weakens the company's debt structure by adding subordinate debt.
-
Financial Distress Context
This agreement occurs as the company faces a 'going concern' warning and is pursuing a large, speculative acquisition, underscoring its precarious financial position and the need to restructure existing obligations.
Analysis · MEHA · Life Sciences
Functional Brands Inc., a micro-cap company facing a going concern warning, has modified the terms of its Series C Convertible Preferred Stock. The conversion price was reduced to $0.1636 per share, and a prohibition on below-price conversions was waived, increasing potential dilution for common shareholders. Critically, the company is capitalizing unpaid cash consideration from a prior agreement into additional, unsecured principal on existing exchange notes, signaling significant liquidity challenges and a weakening balance sheet. This comes amidst a pending, massive acquisition, underscoring the company's precarious financial position.
At the time of this filing, MEHA was trading at $0.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.08 to $8.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.